Panobinostat
Adult Anaplastic Oligodendroglioma
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Adult Anaplastic Oligodendroglioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BBB |
(+)-VINCRISTINE Novartis Pharmaceuticals | Phase 2 | BBB |
Irinotecan City of Hope Medical Center | Phase 2 | BB |
Ziv-Aflibercept National Cancer Institute (NCI) | Phase 2 | B |
Temsirolimus Andrew B Lassman, MD | Phase 1/2 | B |
View all 33 →
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →